Welcome to our dedicated page for Tourmaline Bio news (Ticker: TRML), a resource for investors and traders seeking the latest updates and insights on Tourmaline Bio stock.
Tourmaline Bio Inc reports clinical, financial, and corporate developments for a late-stage biotechnology company focused on immune and inflammatory diseases. Its recurring updates center on pacibekitug, also referred to as TOUR006, including data from the Phase 2 TRANQUILITY trial in cardiovascular inflammation and program activity in thyroid eye disease.
Company news also covers quarterly financial results, business highlights, scientific meeting presentations, biomarker data involving high-sensitivity C-reactive protein and IL-6 pathway activity, advisory-board activity, material agreements, governance matters, shareholder voting topics, capital-structure disclosure, and risk factors tied to its clinical-development strategy.
Tourmaline Bio announced the promotion of Ryan Robinson, CPA, to Chief Financial Officer and Treasurer, effective June 25, 2024. Robinson has been with Tourmaline since last summer and has served as the Interim CFO and Treasurer since October 2023. He played a key role in Tourmaline's growth, including a reverse merger in October 2023 and a $172.5 million public offering in January 2024. Robinson brings nearly 15 years of biotech finance and operations experience, having worked at Korro Bio, Jounce Therapeutics, and Merrimack Pharmaceuticals. He holds a B.S. in Management and an M.S. in Accounting from Boston College and is a CPA.
Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company, announced that its CEO, Sandeep Kulkarni, will present at the Jefferies Global Healthcare Conference in New York. The presentation is scheduled for Thursday, June 6, 2024, at 2:30 pm ET. A live webcast and replay will be available on the Tourmaline Bio website.
Tourmaline Bio has dosed the first patient in its Phase 2 TRANQUILITY trial for TOUR006, a monoclonal antibody targeting IL-6 to treat atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular conditions. This randomized, double-blind, placebo-controlled trial involves patients with high inflammatory risk and chronic kidney disease. The trial aims to assess the drug's safety, pharmacokinetics, and pharmacodynamics, with results anticipated in the first half of 2025. If successful, TOUR006 could advance to Phase 3 by 2025, offering quarterly subcutaneous dosing and potentially positioning itself as a best-in-class treatment for ASCVD and related conditions.
Tourmaline Bio, Inc. reported its Q1 2024 financial results and recent business highlights. Initiatives include a Phase 2 trial for ASCVD and TED, a successful public offering, and $350.3 million in cash reserves. The company aims to improve the lives of patients with immune and inflammatory diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.